Senti Biosciences Holdings, Inc. (SNTI) News
Track canonical SquawkNews coverage tagged to SNTI, Senti Biosciences Holdings, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Senti Biosciences gets Nasdaq noncompliance notice; trading continues
Senti Biosciences Holdings received Nasdaq notices for failing the $1.00 minimum bid price and $2.5 million stockholders’ equity requirements for the Nasdaq Capital Market. Trading continues under SNTI, with until Feb 23
EQUITY | Sep 02, 2026, 08:36 PM UTC
M
Senti Biosciences clears $2M third-tranche note sale to NSG
Senti Biosciences amended its Securities Purchase Agreement on September 1, 2026 to permit senior secured convertible notes in more than two tranches, authorizing a $2.0 million third-tranche issuance to NSG BioInnovatio
EQUITY | Sep 02, 2026, 08:36 PM UTC
L
SNTI Senti Biosciences - cvr milestones: $10M for BLA filing, $20M for FDA approval, $30M for $200M sales
SNTI Senti Biosciences - cvr milestones: $10M for BLA filing, $20M for FDA approval, $30M for $200M sales
REGULATION | Jul 15, 2026, 11:30 AM UTC